With the end of the year, the flashback to the transformative trends has been a memorable positive change in the healthcare sector that brought new hope and modernisation upgrade to the individuals’ good health, elevating their lifestyle. The tremendous impact in the biotech and pharma world was the landmark obesity drug deals, AI’s involvement in the pharma operations, including China’s biotech surge that redefined the life sciences and welcomed new transformation into the operations.
The main talk of the billion-dollar transactions, profitable clinical breakthroughs, and popular policy shifts proved that the biotech and pharma have turned into a dynamic topic that draws the attention of every healthcare expert in 2025. As observed, strategy and science, when and where met, the key developments worked as a magic wand, sparking industry-wide debate and conversation.
This year, weight-loss treatment and medicines were in heavy demand, and so the experts were focusing their efforts to chase the best and effective solutions to meet this demand. The recent news of Pfizer’s brilliant $10 billion acquisition of Metsera, an obesity drug developer, will remain an unforgettable year filled with obesity drug development initiatives.
In August, the popular Eli Lilly put major efforts to make the GLP-1 class a part of mainstream by cracking $1.3 million deal with Superliminal, a Boston-based start-up to accelerate its AI/ML potential to create a new small molecule obesity drug.
After taking careful steps in 2024, the partnership paved the way to 2025 healthcare excellence. The pharma leaders gave billions from their pockets to take over or collaborate with biotech focusing on obesity severity, rare disease, oncology and neurology. Johnson & Johnson made a position in the trend list with its acquisition of neurology leader Intra-Cellular Therapies. Whereas China came into the limelight with its major innovation hub during the healthcare emergency.
China is a famous hub of attentive pharmaceutical ingredient development in the pharma supply chain. Apart from China, many popular companies were involved in various deals.
The new modalities, real marketing momentum, are one of the popular trends. The cell and gene therapy (CGT) was supposed to hit the ground in 2025 as analysts' expectations rose after the FDA’s approval for Sarepta Therapeutics’ Elevidys in mid-2024 for Duchenne muscular dystrophy (DMD). Lastly, the convergence of Biotech/Pharma and AI operations became an essential part in supporting the drug discovery process and leveraging innovation throughout manufacturing and development.
Holding M.Pharm in Pharmaceutical Chemistry, Chandni crafts cutting-edge, research-driven healthcare news for Towards Healthcare, combining scientific depth with innovative storytelling to simplify complex topics for global readers.
